EUROPE’S ANTIBIOTIC INVESTMENTS STAGNATE AS RESISTANCE CRISIS LOOMS

By Jonathan Smith at Labiotech.eu Despite the urgent danger of antibiotic resistance, investments into European biotech antibiotic players have remained flat. However, growing regulatory and societal awareness could spell fresh investments in the coming years. Over the last decade, pressure has been mounting on healthcare systems as infectious microbes become harder and harder to fight […]
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No 966627 (OMNIX MEDICAL).